Aradigm
aradigmhealth.com
Actively hiring
Cell & Gene Therapy
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Andreessen Horowitz
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
Backed byfrom the funds' portfolios and accelerator catalogs
Andreessen Horowitz Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Instant Quantification of genetic modifications for Cell and Gene Therapies.
Capsida Biotherapeutics is an industry-leading gene therapy platform company creating a new class of targeted, non-invasive gene therapies…
Stately Bio is developing the next generation of life-saving regenerative medicines with the world.
Vyriad engineers targeted virus platforms that bring durable in vivo gene therapies, genome editing, and oncolytic virotherapies to…
Designer cell therapies for pets first and their people next.
MediSix Therapeutics develops innovative T-cell therapies using its proprietary PEBL technology platform. An IASO Biotechnology subsidiary.
Overview
Benefits platform for cell and gene therapies designed to provide sustainable access to life-saving medicines.
News
Aradigm Launches First-of-Its-Kind Platform to Provide Sustainable Access to Life-Saving Cell and Gene Therapies
Company Closes $20 Million Series A Led by Frist Cressey Ventures and backed by Morgan Health and Andreessen Horowitz
Read more
Report
Aradigm Announces Conditional Approval For The Combined Chapter 11 Plan And Disclosure Statement
Read more
Report
Where Aradigm Corporation (NASDAQ:ARDM) Stands In Terms Of Earnings Growth Against Its Industry
When Aradigm Corporation (NASDAQ:ARDM) announced its most recent earnings (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of its industry peersRead More...
Read more
Report
3 Reasons Why Aradigm Corporation (ARDM) is a Great Momentum Stock
Aradigm Corporation is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
Read more
Report
Aradigm Shareholders Approve Collaboration Transaction With Grifols, S.A. to Develop and Commerciali
Read more
Report
Show more news